A promising but controversial new approach to treating blood cancer could be in trouble in the earliest innings of human testing after Celgene pulled the plug on a trailblazing clinical trial.

On Monday, Celgene (CELG) terminated a Phase 1 study of CC-90002, which targets a protein that helps cancer cells stay out of the immune system’s crosshairs. In an update to ClinicalTrials.gov, Celgene said it canceled the CC-90002 study because early results “did not offer a sufficiently encouraging profile” to move forward.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy